Sanofi to acquire Inhibrx for $1.7B - Endpoints News
- Sanofi to acquire Inhibrx for $1.7B Endpoints News
- Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal STAT
- Sanofi inks $1.7B Inhibrx buyout, snagging rare disease drug but spinning out cancer programs FierceBiotech
- France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 billion Reuters.com
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B PR Newswire